EP1771203A4 - Inhibition von nf-kb - Google Patents

Inhibition von nf-kb

Info

Publication number
EP1771203A4
EP1771203A4 EP05791579A EP05791579A EP1771203A4 EP 1771203 A4 EP1771203 A4 EP 1771203A4 EP 05791579 A EP05791579 A EP 05791579A EP 05791579 A EP05791579 A EP 05791579A EP 1771203 A4 EP1771203 A4 EP 1771203A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05791579A
Other languages
English (en)
French (fr)
Other versions
EP1771203A2 (de
Inventor
Andrei V Gudkov
Katerina V Gurova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of EP1771203A2 publication Critical patent/EP1771203A2/de
Publication of EP1771203A4 publication Critical patent/EP1771203A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
EP05791579A 2004-07-20 2005-07-20 Inhibition von nf-kb Withdrawn EP1771203A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58963704P 2004-07-20 2004-07-20
PCT/US2005/025884 WO2006012419A2 (en) 2004-07-20 2005-07-20 Inhibition of nf-kb

Publications (2)

Publication Number Publication Date
EP1771203A2 EP1771203A2 (de) 2007-04-11
EP1771203A4 true EP1771203A4 (de) 2010-06-02

Family

ID=35786698

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05791579A Withdrawn EP1771203A4 (de) 2004-07-20 2005-07-20 Inhibition von nf-kb

Country Status (4)

Country Link
EP (1) EP1771203A4 (de)
JP (3) JP2008507545A (de)
AU (1) AU2005267117C1 (de)
WO (1) WO2006012419A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008090417A2 (en) * 2006-02-02 2008-07-31 The Cleveland Clinic Foundation Inhibition of nf-kb
WO2009143290A2 (en) * 2008-05-20 2009-11-26 Cleveland Biolabs, Inc Inducing cell death by inhibiting adaptive heat shock response
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
GR1006794B (el) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
WO2011031974A1 (en) * 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
KR101812952B1 (ko) * 2016-09-07 2017-12-28 부산대학교 산학협력단 퀴나크린을 유효성분으로 함유하는 난치성 암 예방 또는 치료용 조성물
CN115212209B (zh) * 2021-04-19 2023-11-28 中国科学院分子细胞科学卓越创新中心 一种具有免疫佐剂活性和促进免疫疗法的抗肿瘤药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059482A2 (en) * 2005-11-14 2007-05-24 Cleveland Clinic Foundation Modulation of immune responses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131066A (ja) 1999-08-25 2001-05-15 Nippon Kayaku Co Ltd アポトーシス増強剤
CA2478302C (en) * 2002-03-07 2009-02-03 Samjin Pharmaceutical Co., Ltd. 9-aminoacridine derivatives and process for the preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059482A2 (en) * 2005-11-14 2007-05-24 Cleveland Clinic Foundation Modulation of immune responses

Also Published As

Publication number Publication date
AU2005267117B2 (en) 2012-06-21
EP1771203A2 (de) 2007-04-11
AU2005267117A1 (en) 2006-02-02
JP2011219499A (ja) 2011-11-04
WO2006012419A2 (en) 2006-02-02
AU2005267117C1 (en) 2012-10-25
JP2014074056A (ja) 2014-04-24
WO2006012419A3 (en) 2007-03-08
JP2008507545A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
SG152225A1 (en) Inhibitors of iap
IL179854A0 (en) Inhibitors of iap
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
SG156674A1 (en) Asphaltene inhibition
IL179398A0 (en) Dpp-ib inhibitors
EP1756092A4 (de) Neue inhibitoren von rho-kinasen
EP1788874A4 (de) Salze von 5-azacytidin
AU304443S (en) Toilet
EP1771203A4 (de) Inhibition von nf-kb
GB0421355D0 (en) Inhibitors
AU303116S (en) Toilet
GB0421356D0 (en) Inhibitors
IL196187A0 (en) NF-kB INHIBITOR
GB0405228D0 (en) Bathing aid
GB0511809D0 (en) Toilet
GB2414745B (en) Euroblock - flood prevention specification
GB0404518D0 (en) Protection of sanitaryware
GB0410299D0 (en) Inhibition of biofilm formation
GB0419432D0 (en) Shower protected airer
GB0400043D0 (en) Shower protected airer
GB0403286D0 (en) Shower protected airer
GB0412138D0 (en) Definition of zeroclick
ZA200900104B (en) NF-KB inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070207

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20070308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20070410BHEP

Ipc: A01N 43/42 20060101AFI20070410BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100504

17Q First examination report despatched

Effective date: 20110624

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101ALI20141023BHEP

Ipc: A61K 31/17 20060101AFI20141023BHEP

Ipc: A61K 31/435 20060101ALI20141023BHEP

Ipc: G01N 33/50 20060101ALI20141023BHEP

Ipc: A61K 38/17 20060101ALI20141023BHEP

18D Application deemed to be withdrawn

Effective date: 20140429

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20150429